Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes

19 avril 2022 mis à jour par: Yale University
We propose conducting a pilot randomized study to assess the feasibility of using the automated insulin dose adjustment (AIDA) system to assist the parents of children with Type 1 Diabetes to make insulin dose adjustments between visits with their diabetes provider. Study results will be used to inform a larger RCT with an anticipated primary outcome of change in HbA1c in patients managed with either standard care (changes in therapy settings effected at regularly scheduled patients visits) or AIDA guided care.

Aperçu de l'étude

Statut

Retiré

Les conditions

Intervention / Traitement

Description détaillée

Screening & End of 3-Week Run-in Period (Visit 1, Week 0) : Screening will be conducted by invitation to potentially eligible subjects. The study will be explained and written informed consent will be obtained from parents or patients (when 18 years of age or older) prior to conducting any study-related procedures. After written informed consent and patient assent (when <18 years of age) have been obtained, potential participants will undergo a history and physical exam. Girls of childbearing potential will have a urine pregnancy test performed at the time of the enrollment visit and the need for contraception for the entire duration of the study will be discussed. At this and all other study visits, participants/parents will meet with a diabetes care provider (i.e., a physician, nurse practitioner, or physician assistant) who will carry out a comprehensive review of diabetes management and review blood glucose and ketone records. The treatment regimen will be adjusted as clinically indicated during the initial screening visit and baseline data (including CGM and insulin dose data) will be collected in all participants during the 3-week run-in period of the study; HbA1c levels will be measured at the end of the 3-week baseline period in all eligible participants.

Baseline data obtained at the screening or 3-week baseline visit will include:

  • Demographic characteristics, including family income, highest parental education attained, and number of individuals in the home
  • 3-week data regarding CGM, insulin dose and Fitbit data
  • Anthropometric measures (height, weight, BMI, vital signs) and physical exam
  • Current diabetes care practices (frequency of self-monitored blood glucose (SMBG), insulin dosing, review of blood glucose values)
  • Medical History: duration of diabetes, comorbidities, past medical history, social history, family history, medications, and allergies
  • Additional diabetes history including current/past use of CGM, insulin pump, and other modes of diabetes technology
  • Frequency of Emergency Department visits due to decompensated diabetes (i.e., hyperglycemia, ketosis and DKA) over the past 6 months
  • Baseline laboratory assessment including lipid panel and urine microalbumin

  • Psychosocial Questionnaires will be administered

    1. Hypoglycemia Fear Survey (parent and child)
    2. Pittsburgh Sleep Quality Index
    3. Diabetes Treatment Satisfaction Questionnaire (DTSQ, DTSQc), which includes eight items, six of which form a scale (scored 0-36) in which higher scores indicate greater treatment satisfaction
    4. Diabetes-specific emotional distress using Problem Areas in Diabetes scale

After collection of all baseline data, eligible participants will be randomized to either the control or intervention group and receive instructions for the study. Participants will also be provided with a FitBit and instructed to wear this for the duration of the study to track activity levels. Participants in the intervention group will be required to upload their diabetes devices to Tidepool each week for the duration of the study. Tidepool is program used at Yale Pediatric Diabetes clinics as the current standard of care for uploading devices (pumps, CGMs, Bluetooth enabled pens) in our clinics and is HIPAA compliant. Participants may contact the Yale Diabetes Team for insulin dose adjustments or the study team at any point during the study if they have a question about the study.

Visit 2 (Week 13) & Visit 3 (Week 26): At these visits, all participants will meet with a diabetes care provider who will carry out a comprehensive review of diabetes management and review blood glucose and insulin records. Diabetes devices will be downloaded, and glycemic trends and insulin dosing regimens will be reviewed. The treatment regimen will be adjusted as clinically indicated.

After 26 weeks in the study, intervention group parents will be asked to participate in focus groups to discuss the study. These meetings will take place at the Yale Pediatric Diabetes Research Center.

Type d'étude

Interventionnel

Phase

  • N'est pas applicable

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

7 ans à 21 ans (Enfant, Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

i. Clinical diagnosis of type 1 diabetes for at least 1 year ii. Ages 7-21 years iii. Participants 18 years of age must be able to read and provide written consent iv. Participants under 18 years of age must be able to read and provide written assent v. Participants are managed using an insulin pump or multiple daily injections vi. Participant has a CGM or is willing to wear a CGM for the duration of the study

Exclusion Criteria:

I. Hemoglobin A1c <7.5% or > 10.0% ii. Recent history of more than 1 episode of diabetic ketoacidosis (DKA) in the past 4 months iii. Treatment with glucose lowering drugs other than insulin iv. Females who are pregnant, lactating, or planning to become pregnant in the next 6 months v. Another medical condition that precludes participation in the study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Automated Insulin Dose Adjustment (AIDA)
Using the AIDA system to assist the parents of children with T1D make insulin dose adjustments
Dispositif: Automated Insulin Dose Adjustment
The system originally developed at Boston Children's Hospital, obtains CGM, insulin delivery, and activity data, from the cloud each day at approximately 8:00 PM using an Application Program Interface (API) calls to commercial companies (primarily Glooko and Tidepool) that aggregate data from different devices used to manage glucose levels in individuals. A detailed statistical and control analysis (see preliminary data study 1 for algorithm details) of the data are then conducted to determine if a change in therapy is required. If the analysis indicates a change in therapy is required, the patient or parent is notified by text or email directing then to a web portal detailing the change. The patient or parent can accept or modify the recommended change. If a change is made, the AIDA system confirms that the change is correctly implemented into the patient's pump or Bluetooth enabled pen when the patient next uploads the device data to the cloud.
Comparateur actif: Control
Standard Care - change in therapy settings effected a regularly scheduled patients visits
Dispositif: Control
Standard Care - change in therapy settings effected at regularly scheduled patient visits

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Percent of patients at target range from baseline to 13 week
Délai: 13 weeks
Based on continuous glucose monitoring. Target range is defined as 70- 180 mg/dL
13 weeks
Percent of patients at target range from baseline to 26 weeks
Délai: 26 weeks
Based on continuous glucose monitoring. Target range is defined as 70- 180 mg/dL
26 weeks

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change from baseline in HbA1c
Délai: 13 weeks
This outcome will determine if there was a change in HbA1c levels from baseline to 13 weeks based on continuous glucose monitoring
13 weeks
Nighttime hypoglycemic defined as the % of time spent <55 mg/dL
Délai: Baseline
Based on continuous glucose monitoring
Baseline
Nighttime hypoglycemic defined as the % of time spent <55 mg/dL
Délai: 13 week
Based on continuous glucose monitoring
13 week
Nighttime hypoglycemic defined as the % of time spent <55 mg/dL
Délai: 26 week
Based on continuous glucose monitoring
26 week
Nighttime hypoglycemic defined as the % of time spent under 70 mg/dL
Délai: Baseline
Frequency of nighttime hypoglycemic events
Baseline
Nighttime hypoglycemic defined as the % of time spent under 70 mg/dL
Délai: 13 week
Frequency of nighttime hypoglycemic events
13 week
Nighttime hypoglycemic defined as the % of time spent under 70 mg/dL
Délai: 26 week
Frequency of nighttime hypoglycemic events
26 week
Percent of the recommendations that are accepted or modified by the family
Délai: 26 week
Percent of the recommendations that are accepted or modified by the family
26 week
Hypoglycemia Fear Survey
Délai: 26 weeks
This will be administered to the child and parent. The survey consists of 23 questions. Questions are answered using a 5 point likert scale ranging from never, rarely, sometimes, often, and always. The administration time is 10 minutes. The higher scores entail greater worry.
26 weeks
Pittsburgh Sleep Quality Survey (PSQI)
Délai: 26 weeks
The survey consists of 10 questions. The Questions relate to usual sleep habits over the last month, including time it takes to fall asleep, usual bedtime, hours of sleep per night, as well as questions about the frequency of sleep issues (not during the past month, less than once per week, once or twice per week, or three or more times per week). Higher scores suggest poorer sleep quality. The administration time is 5 minutes.
26 weeks
Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Délai: 26 weeks
This will be administered to the parent and teen. The survey consists of 12-24 questions that are based on a likert scale ranging from 0 to 6. Higher scores entail greater satisfaction. The administration time is 10 minutes.
26 weeks
Problem Areas in Diabetes Scale (PAID)
Délai: 26 weeks
This is a questionnaire with 20 questions scaled from 0 to 4 on a likert scale. Questions involve feelings and emotional distress related to diabetes. Higher scores entail a more serious problem related to diabetes. The Administration time is 5 minutes.
26 weeks

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Yale University

Collaborateurs

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Les enquêteurs

  • Chercheur principal: Laura Nally, MD, Yale University

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Anticipé)

1 septembre 2022

Achèvement primaire (Anticipé)

1 avril 2023

Achèvement de l'étude (Anticipé)

1 avril 2023

Dates d'inscription aux études

Première soumission

5 février 2020

Première soumission répondant aux critères de contrôle qualité

5 février 2020

Première publication (Réel)

6 février 2020

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

27 avril 2022

Dernière mise à jour soumise répondant aux critères de contrôle qualité

19 avril 2022

Dernière vérification

1 avril 2022

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • 2000027002
  • 2K12DK094714-06 (Subvention/contrat des NIH des États-Unis)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur Diabète de type 1

Rechercher des essais similaires

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

CROs by country

CROs in Argentina

Conditions

Maladies rares

Interventions en matière de drogue

Compléments alimentaires

Commanditaire / collaborateurs

Emplacements

3
S'abonner